Kyle Bryant Translational Research Award supports investigators developing Friedreich’s ataxia therapies and tools to move candidates toward clinical study and overcome therapy-development bottlenecks.
Funder: Friedreich's Ataxia Research Alliance
Due Dates (Anticipated): February 2027 (LOI) | April 2027 (Full application)
Funding Amounts: Up to $200,000 per year for 1 or 2 years; up to one award annually
Summary: Supports translational Friedreich’s ataxia research advancing therapeutic candidates toward clinical study or overcoming critical therapy-development bottlenecks.
Key Information: Preclinical therapeutic testing requires established proof of concept; an LOI is required before full application.
The Kyle Bryant Translational Research Award is administered by the Friedreich’s Ataxia Research Alliance (FARA) to accelerate the translation of basic discoveries into clinical applications for Friedreich’s ataxia (FA). Honoring Kyle Bryant’s efforts, it supports translational-stage activities needed to move therapeutic candidates into clinical study and novel tools that address critical bottlenecks in therapy discovery or development.
Supported work includes preclinical development and testing of therapeutics, biologics, and devices in cells and animals after proof of concept has been established. Projects may also develop therapeutic-delivery technologies, identify pharmacodynamic, monitoring, or diagnostic biomarkers, or establish novel clinical endpoints. These approaches may facilitate clinical development, clarify disease variability, severity, and prognosis, or improve trial participant selection. Clinical studies of patient outcome measures are also supported.